SEC Company Response from Corbus Pharmaceuticals Holdings, Inc. (CRBP) (CIK 0001595097) (CRBP) — Nov 18, 2015
Corbus Pharmaceuticals Holdings, Inc. (CRBP) (CIK 0001595097)
Date: Nov. 18, 2015 · CIK: 0001595097 · Accession: 0001193125-15-380820
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-207936
Letter
Correspondence
Corbus Pharmaceuticals Holdings, Inc.
100 River Ridge Drive
Norwood, MA 02062
November 18, 2015
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Corbus Pharmaceuticals Holdings, Inc.
Registration Statement on Form S-3 (File No. 333-207936)
Filed on November 10, 2015
Ladies and Gentlemen:
In accordance with Rules 460 and 461 under the Securities Act of 1933, as amended, Corbus Pharmaceuticals Holdings, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission (the “Commission”) at 4:30 p.m., Eastern Standard Time, on November 19, 2015, or as soon as practicable thereafter.
In connection with the acceleration of the Registration Statement, the Company hereby acknowledges the following:
•
should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
•
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
•
the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Please call Steven M. Skolnick of Lowenstein Sandler LLP at (973) 597-2476 to confirm the effectiveness of the Registration Statement or with any questions.
Very truly yours,
CORBUS PHARMACEUTICALS HOLDINGS, INC.
Show Raw Text
CORRESP 1 filename1.htm Correspondence Corbus Pharmaceuticals Holdings, Inc. 100 River Ridge Drive Norwood, MA 02062 November 18, 2015 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Corbus Pharmaceuticals Holdings, Inc. Registration Statement on Form S-3 (File No. 333-207936) Filed on November 10, 2015 Ladies and Gentlemen: In accordance with Rules 460 and 461 under the Securities Act of 1933, as amended, Corbus Pharmaceuticals Holdings, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission (the “Commission”) at 4:30 p.m., Eastern Standard Time, on November 19, 2015, or as soon as practicable thereafter. In connection with the acceleration of the Registration Statement, the Company hereby acknowledges the following: • should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; • the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and • the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Please call Steven M. Skolnick of Lowenstein Sandler LLP at (973) 597-2476 to confirm the effectiveness of the Registration Statement or with any questions. Very truly yours, CORBUS PHARMACEUTICALS HOLDINGS, INC. By: /s/ Sean Moran Name: Sean Moran Title: Chief Financial Officer